Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of antibodies after a third COVID-19 vaccine dose and safety/immunogenicity of a fourth dose
RBR-4b5kzhdPhase 4Not yet recruiting
- Sponsor
- Instituto D’Or de Pesquisa e Ensino
- Start
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, ChAdOx1 nCoV-19, coronavac and Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Instituto D’Or de Pesquisa e Ensino. Primary endpoints: Antibody persistence at 6 months or more after third dose, Safety after fourth dose and 1 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
tozinameranChAdOx1 nCoV-19coronavacAd26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-4b5kzhd.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4b5kzhd.